The Hidden Reason Sites are Firing Recruiters

 What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal liability. We break down the MSO structures that are failing, the "Red Zones" in state law, and how KLF re-architects your contracts to make you the safest, most scalable partner in the life sciences industry. 

Transcript

Darshan 0:00

What would happen if your clinical trial sites were suddenly banned from using patient recruiters? Imagine this: you run a patient recruitment company, and suddenly you can't operate. Not operate the way you've always had. This is a real-world scenario that's hiding inside fee splitting laws, the corporate practice of medicine doctrine, and the way MSO structures are tightening across multiple states. Now, depending on how your contracts are set up, regulators may be closer to that outcome than you actually think. Hi, I'm Darshan, and today we're unpacking exactly how this could happen, what risks are creeping into the patient recruitment world from the physician side of the industry, and how you can safeguard the entire business model. We're gonna talk state law, fee splitting, MSO structures, and your role as a recruitment partner to sites and investigators. And we're gonna do all this with one goal protecting you, the sites you support, and the physicians you rely on to run research. So why does this matter to recruitment companies? If you recruit patients for clinical trial sites, your value is obvious. You fill enrollment gaps, you speed timelines, and you keep trials moving. But financial relationships between you and the site often intersect with physician income streams. They intersect with sponsor payments and clinical oversight. And that is where regulators start to care. Recruitment firms sometimes assume that the risk sits entirely in the site or the PI. But if your compensation structure mimics referral fees, if you're tied to clinical revenue in any way, or if the site's MSO arrangement pulls you indirectly into the clinical side, you're suddenly part of the same risk pool. And that is the ecosystem we're uncovering today. Now, let's start with the corporate practice of medicine. In many states, only licensed physicians or physician-owned entities can control, direct, or profit from the practice of medicine. Non-physician companies cannot own a medical practice outright or influence clinical decisions. This is why sites should use an MSO structure and they must meet and keep clinical control firmly inside the physician's entity. If your recruitment contract unintentionally positions you as influencing clinical flow, staffing, or patient steering, you are stepping into CPOM territory without meaning to. Let's talk about fee splitting prohibition. When a physician shares part of the clinical fee with someone else for referring patients, regulators can get very interested. Many states treat payment per recruited patient as dangerously close to a referral bounty, especially if there's a link between your payment and the physician's revenue or sponsor reimbursements. This is where recruitment companies often get blindsided. A simple pay per randomized patient clause that looks efficient, but in many states it looks like a fee split. MSO structures and the revenue track. Most compliant physician practices use a management services organization that handles operations, billing, HR, marketing, and other non-clinical tasks. But MSOs have a strict rule. Their fees must be fair market value and not tied to the clinical size revenue. Most small sites don't do this, and most large practices do. If a recruitment partner plugs into an MSO arrangement in a way that creates revenue-based incentives, the MSO and the recruiter both risk getting labeled as revenue sharers in the physician's clinical activity. Now, how does all this come together for patient recruiters? Imagine that a state suddenly starts tightening enforcement, and this is happening. Licensing boards and attorney generals are generally increasing scrutiny into referral relationships, into revenue sharing, and MSO structures.

SPEAKER_00 4:11

Enjoying our content, we'd love to hear more. Please like, comment, share, and find more.

Darshan 4:18

Let's say that a site reads one of these warnings and they call their lawyer. That lawyer is going to look at the recruitment contract and say, your recruiter is paid per enrollment patient. That looks like fee splitting. Shut it down. Suddenly, your pipeline is gone. Not because you did anything malicious, but because the structure looked wrong on paper. Now if one site pulls back, others follow. And now you're staring at the original question all over again. What would happen if your clinical trial sites were suddenly banned from using patient recruiters? You lose access, sites lose enrollment, sponsors lose timelines, everyone loses. And that's where KLF fits in. At the Kulkarni Law Firm, we protect the entire chain. KLF's role in this landscape is very straightforward. You protect a model. The site's model, the physician's model, and your recruitment model. And here's how we do it: we clean up your payment structures. You often need to redesign contracts so that your compensation reflects fair market value for non-clinical services, not referral fees or disguised revenue splits. So you cannot use percentages. No indirect fee share optics, just clean, service-based terms that regulators understand. Then we build documentation that keeps you safe. We need to look at your processes and outline them specifically. We'd spell out every task you perform as a non-clinical vendor. This means outreach, targeting, advertising, digital funnels. When the state looks, they should see a service provider, not a referral partner. We integrate you into the MSO model safely. If your clients use MSOs and most of them don't, we will make sure that your fees aren't accidentally tied to the clinical revenue. You want to stay on the administrative side. You want to stay compliant. This way, everyone stays operational. Then we're gonna map state law differences and give you a real compliance plan. California's rules are not Florida's rules. Texas's rules are not New York's. We are going to give you a state-by-state map with green zones, yellow zones, and the absolutely not zones. We position you as a safe choice for sponsors and sites. Your model is clean, you're suddenly the vendor everyone has to match, and that's how you grow. Follow our page on LinkedIn. So what are the key takeaways? Recruitment companies sit closer to fee splitting than most real huts. States are actively tightening enforcement, especially when MSOs are used, and if they are not used, you have other problems on your hands. A simple tweak in contract structures, that can be the difference. Difference between compliant and prohibited. Sites that panic will cut off external recruiters and you will be exposed and they will be exposed. That's why you need protection before this happens. The Kilkarney Law Firm positions you as compliant, trustworthy, and ready for scale. So again, let's ask yourself this. What would happen if your clinical trial sites were suddenly banned from using patient recruiters? And here's the better question. What would happen if you don't partner with someone who makes sure that this never happens? If you want to protect your model, you want to safeguard your site relationships, and you want to build a structure that scales without legal surprises, we break this down every week in ways that keep you ahead of regulators, ahead of competitors, and ahead of the curve. Call, click, click or email.